Fecal Occult Testing Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Fecal Occult Testing Market size was worth USD 1 billion in 2022 and is poised to record substantial growth at 5.3% CAGR from 2023-2032, driven by the increasing prevalence of rectal & colon cancer.
Fecal occult testing, also referred to as fecal occult blood testing (FOBT), is a vital medical diagnostic procedure designed to identify minute quantities of concealed blood in stool samples. The existence of such concealed blood can serve as an indicative factor for various gastrointestinal (GI) conditions, encompassing colorectal cancer, polyps, ulcers, and other related disorders. This procedure involves the collection of a stool sample, followed by chemical reactions that reveal the presence of blood. Positive outcomes from this test lead to further diagnostic measures to pinpoint the underlying cause of the blood in the stool, thereby facilitating early detection and subsequent treatment.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Fecal Occult Testing Market size in 2022: | USD 1 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 7.3 |
| 2023 Value Projection: | USD 2 Billion |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 205 |
| Tables, Charts & Figures: | 270 |
| Segments Covered: | Test Type, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The rising incidence of rectal and colon cancer is a significant driver for the market. Colorectal cancer is one of the most common cancers globally, and early detection plays a crucial role in improving patient outcomes. Fecal occult testing serves as a non-invasive and relatively simple method for detecting hidden traces of blood in the stool, which can be an early indicator of colorectal cancer. Furthermore, the growing preference for convenient and patient-friendly point-of-care testing (POCT) and non-invasive diagnostics has propelled fecal occult testing into prominence. Being non-invasive and easily conducted in clinics and primary care settings, fecal occult testing aligns perfectly with this trend. Its simple sample collection process and lack of specialized equipment needs make it ideal for point-of-care use. This upsurge in demand for non-invasive testing has consequently elevated fecal occult testing's adoption as a favored screening method.
The COVID-19 pandemic had a positive impact on the fecal occult testing market, driving substantial market progress. Heightened healthcare awareness during the pandemic underscored the significance of early disease detection and prevention, aligning well with the non-invasive nature of fecal occult testing. With a focus on minimizing exposure risks, the preference for non-invasive diagnostics surged, making fecal occult testing an attractive option for individuals seeking regular health check-ups. The shift towards point-of-care and remote testing, along with its integration into telemedicine platforms, further boosted its appeal.
Additionally, the pandemic's emphasis on healthcare preparedness elevated the importance of early intervention, positioning fecal occult testing as a key tool in identifying conditions including colorectal cancer in their early stages. These factors collectively indicated a positive trajectory for the market's growth as individuals became more health-conscious and healthcare systems prioritized early detection and prevention strategies.
Several governments and healthcare organizations are recognizing the importance of addressing colorectal cancer as a public health concern. They are implementing various initiatives, including awareness campaigns, educational programs, and policies that encourage regular cancer screening. For instance, Centers for Disease Control and Prevention (CDC) and their partners actively promote colorectal cancer prevention through screening, educational campaigns such as Screen for Life, funding research, and state programs. These efforts are not only raising awareness among the general population but also creating a supportive environment for healthcare providers to offer and promote fecal occult testing as a part of routine screening programs.
Furthermore, the U.S. Department of Health and Human Services (HHS) announced the allocation of USD 5 million to support community health centers. This funding, provided by HHS's Health Resources and Services Administration, aimed to enhance the accessibility of vital cancer screenings, ensuring equitable access to life-saving screening services. Therefore, the alignment between government initiatives and the market's growth is evident, as these efforts lead to increased demand and utilization of these tests.
The fecal occult testing market by test type is categorized into guaiac FOB stool test, immuno-FOB agglutination test, lateral flow immuno-FOB test, and immuno-FOB ELISA test. The guaiac FOB stool test segment garnered USD 381.3 million revenue size in the year 2022. Its established reputation in medical practice, affordability, ongoing refinements, and historical integration into colorectal cancer screening programs have collectively propelled its prominence. Additionally, the test's familiarity among healthcare professionals, cost-effectiveness, and improvements over time have instilled trust in its effectiveness. Moreover, this dominance is a result of its alignment with historical screening practices, which have further solidified its position as a cornerstone in fecal occult testing.
Based on end-use, the fecal occult testing market is segmented into hospitals, diagnostic centers, and others. The diagnostic centers segment accounted for over 46% revenue share in the year 2022 and is anticipated to witness highest growth during the forecast period. The specialization of diagnostic centers in providing precise diagnostic services has cultivated a reputation for reliability, positioning them as trusted hubs for fecal occult testing and other medical assessments. Their incorporation of advanced technologies and skilled healthcare professionals elevates the accuracy of fecal occult testing results, establishing confidence among patients and healthcare providers, and consequently driving demand for their services.
In addition, their strategic locations in urban and suburban areas bolster accessibility, resulting in increased utilization and market dominance. Therefore, the diagnostic centers' market dominance stems from their specialized focus, technological prowess, convenience, and widespread accessibility, making them pivotal drivers of both market expansion and efficacy in the realm of fecal occult testing.
U.S. fecal occult testing market accounted for USD 353.1 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline. The U.S. dominance in the market is primarily attributed to its highly advanced and well-established healthcare infrastructure, coupled with the increased prevalence of colorectal cancer. For instance, according to the United States Cancer Statistics (USCS), in 2020, the country reported 126,240 new cases of colorectal cancer, and tragically, 51,869 individuals succumbed to this disease. Therefore, this increased incidence of colorectal cancer highlights the critical significance of advocating for the wider adoption of fecal occult tests in U.S.
Furthermore, the nation's concentration of cancer research institutions and proactive education and awareness campaigns further amplify the adoption of these screenings. Ultimately, the U.S.'s leadership in healthcare infrastructure, awareness efforts, advanced technologies, and cancer prevention strategies has positioned it as the market leader, significantly propelling the market trends and efficacy.
Some of the eminent market participants operating in the fecal occult testing market include
These market players are undertaking several growth strategies including partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen their product portfolio as well as gain a competitive edge over others.
By Test Type (USD Million & Units)
By End-use (USD Million)
The above information is provided for the following regions and countries:
HUMASIS.COM, CTK Biotech, Inc., Biopanda Reagents Ltd, Biohit Oyj, CERTEST BIOTEC, Cenogenics Corporation, Alfa Scientific Designs, Inc., Siemens Healthcare GmbH, Jant Pharmacal Corporation., Quidel Corporation, and Wondfo are some of the fecal occult testing companies worldwide.
U.S. fecal occult testing industry crossed USD 353.1 million in 2022 and is projected to expand significantly through 2032 owing to the highly advanced and well-established healthcare infrastructure in the region.
Fecal occult testing industry size reached USD 1 billion in 2022 and will witness 7.3% CAGR through 2032 due to the rising incidence of rectal and colon cancer worldwide.
The guaiac FOB stool test segment garnered USD 381.3 million in the fecal occult testing industry in 2022 on account of its established reputation in medical practice and historical integration into colorectal cancer screening programs.